stockrow
Monday 9 November 2026
Export VNDA’s income statement to Excel — free account
Vanda Pharmaceuticals Inc.
VNDAVanda Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $216.1 million, up 8.72% from fiscal 2024.
- Revenue
- +24.1%
- EPS
- +1.82%
- Free cash flow
- +9.57%
- Total debt
- −16.5%
Quarter to September 2026, against a year earlier
3.82
0.23
+6.41%
Follow VNDA
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.41 | 1.89 | 1.71 | 1.29 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(17.67) | (8.18) | (11.86) | (10.44) | |
P/B ratio |
1.59 | 1.46 | 1.67 | 1.49 | |
Price to Tangible BV |
2.47 | 2.48 | 3.44 | 3.35 | |
EV/Sales |
1.20 | 0.98 | 0.94 | 0.69 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.38) | (1.68) | (1.42) | (1.14) | |
EV/FCF |
(2.35) | (1.55) | (1.32) | (1.06) | |
Quick Ratio |
2.19 | 1.91 | 1.40 | 1.30 | |
Current Ratio |
2.39 | 2.16 | 1.61 | 1.54 | |
Net Debt/EBITDA |
6.94 | 4.24 | 2.77 | 6.91 | |
Debt/Assets |
0.83% | 0.87% | 0.77% | 0.61% | |
Debt/Equity |
0.01 | 0.01 | 0.01 | 0.01 | |
Asset Turnover |
0.38 | 0.41 | 0.42 | 0.47 | |
Operating CF/Net income |
0.21 | 1.03 | 0.50 | 1.26 | |
Capex/Depreciation |
(0.03) | (3.01) | (0.05) | (0.09) | |
Research and Development Expense of Revenue |
50.70% | 54.98% | 73.13% | 39.56% | |
Selling, General and Administrative Expense of Revenue |
110.07% | 132.18% | 142.17% | 85.33% | |
Intangible Assets out of Total Assets |
0.24 | 0.27 | 0.27 | 0.29 | |
Share Based Compensation of Revenue |
3.99% | 4.96% | 4.17% | 3.35% | |
Graham Net Nets |
0.36 | 0.34 | 0.20 | 0.19 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(42.29%) | (58.61%) | (75.65%) | (94.16%) | |
Free Cash Flow Yield |
(21.25%) | (33.42%) | (41.51%) | (50.51%) | |
Revenue per Share |
0.97 | 0.87 | 0.84 | 1.15 | |
Operating CF per Share |
(0.50) | (0.84) | (0.52) | (0.47) | |
Capex per Share |
0.00 | (0.17) | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.50) | (1.02) | (0.52) | (0.48) | |
Cash per Share |
4.48 | 3.40 | 2.82 | 2.32 | |
Shareholders Equity per Share |
5.55 | 4.72 | 3.66 | 3.31 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.55 | 4.72 | 3.66 | 3.31 | |
Free Cash Flow |
(29.52) | (60.44) | (31.26) | (28.75) | |
Working Capital |
202.10 | 157.59 | 100.46 | 83.49 | |
Capital Expenditures |
(0.10) | (10.22) | (0.19) | (0.31) | |
Net Current Asset Value |
185.50 | 140.41 | 72.20 | 56.00 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.20 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
50.84 | 50.74 | 52.34 | 55.43 | |
Average Payables |
53.69 | 52.95 | 63.56 | 54.10 | |
Average Inventory |
1.79 | 1.81 | 1.92 | 1.79 | |
Average Assets |
572.58 | 532.73 | 518.61 | 491.73 | |
Average Common Equity |
432.87 | 396.09 | 353.26 | 332.93 |
Columns are period end dates · fundamentals updated 2 Nov 2026